Ezetimibe + simvastatin versus doubling the dose of simvastatin in high
cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).
Author(s): Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM.
Affiliation(s): Department of Clinical Pathophysiology, University of Florence, Florence, Italy.
Publication date & source: 2010, Cardiovasc Diabetol. , 9:20
BACKGROUND: The primary goal of therapy in patients with hypercholesterolemia and
coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol
(LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in
patients with type 2 diabetes mellitus (T2DM).
METHODS: Adult patients with T2DM and CHD (N = 93) on a stable dose of
simvastatin 20 mg with LDL-C >or= 2.6 mmol/L (100 mg/dL) and
|